140

(36-73), the median performance status (PS) 1 (0-2). No pt had received prior chemo- therapy. 19 pts had loco-regional disease, 18 pts extensive disease. 18 pts had epi- dermoid carcinoma, 12 adenocarcinoma and 7 large cell anaplastic carcinoma. 1 CR and 12 PRS were observed among the 37 evaluab- le pts (35%). The response rate was highest among pts with a PS of 0 (43%) and pts with epidermoid carcinoma (39%). At the preli- minary analysis it was too early to eva- luate response duration and survival. Toxic effects ~bserved were: median WBC-nadir 2.5 x i0- per ~3;3median platelet count- nadir 143 x i0 /mm ; severe vomiting (WHO-grade 3) in 6 pts (16%); mild to mode- rate (WHO-grade 1-2) peripheral neuro- pathy in i0 pts (27%) and severe neuro- toxicity in 2 pts (I pt with paralytic ileus, 1 pt with severe muscle weekness); elevation of the serum creatinine > 125 umol/l in 3 pts.

In conclusion MMC/VDS/DDP is a combina- tion with group wide activity in NSCLC with manageable toxicity.

A Randomized Study of Vindesin (VDS) vs. CCNU, Cyclophosphamide (CTX) and Metho- trexate (~FFX) vs. all 4 Drugs in Adeno- carcinoma of the Lung. CACL). S~rensen, J.B., B~dker, B., Bork, E., Malm- berg, R., Aabo, K., Dombernowsky, P., Hansen, M., Hansen, H.H. Finsen Institute, Herlev Hospital and Bispebjerg Hospital, Copenhagen, Denmark and Renstr~mska Hospi- tal, G~teborg, Sweden.

252 pts with unresectable ACL and no prior chemothearpy or irradiation were randomized after stratification for per- formance status (PS) to either VDS as sing- le drug (A), CCNU, CTX + MTX (B), or CCNU, CTX, MTX + VDS (C).

Dose an~ schedule was the following: A: VDS 4 mg/m i.v. weekl~ for 8 wks, then q 2 wk~, B: CCNU 70 mg/m p.o. + CTX ½000 mg/m- i.v. q 4 wks, and MTX 20 mg/m p.o. day 15 and 18 in each course, C: schedule

was as2in A and B but2the doses were VDS 2 mg/m , CC~U 50 mg/m , CTX 750 mg/m 2 and MTX 20 mg/m .

Hematologic toxicity was mild with WHO grade 1 or 0 as maximum found in 60% (A), 36% (B) and 28% (C). Septicemia occurred only in B (4 pts) and C (3 pts). Dose reduction due to neurotoxicity of VDS was necessary in 50% (A), 0% (B) and 16% (C).

63, 66 and 66 pts, respectively, were evaluable for response. Response rates (CR+PR) were for treatment A 32% (20/63), B 20% (13/66) and C 23% (15/66) (p>0.05). CR was observed in 6 pts in A, and 1 pt in B and C respectively (P<0.05). Duration of response was a median of 16, 17 and 12 wks respectively. Median observation time

is at present 88 wks and median survival

34 wks in each arm. Median survival for pts in PS 0 was 48 wks, PS 1 24 wks, and PS 2 16 wks

(p<0.001). The study confirms that i. VDS is an active

single drug in ACL, and 2. is at least as acti- ve as a combination of CCNU, CTX and MTX or the same 3 drugs+VDS, however duration of response is short (12-17 wks). 3. PS is a major prognostic factor in ACL.

Chemotherapy (CT) of Advanced Non-0at Cell Bronchogenic Carcinoma (NOBC) With Cyclophos- phamide (C), Adriamycin (A), Methotrexate CM) and Procarbazine (P) (CA~P) vs Cis-Platinum CD) and Etoposide (E) (DE): A Randomized Study. Veronesi, A., Magri, M.D., Canobbio, L., Tumo- io, S., T~relli, U., Crivellari, D2, Fassio, T., Ardizz~ni , A., Vaccher, E., Mazza , F., Fran- zolini , P., Grigoletto, E. Centro di Riferi- mento Oncologico, Aviano; i. Istituto Tumori, Genova. 2. Division of Pneumology, Pordenone,

Italy. Patients (pts) with advanced NOBC were ac-

crued at 2 cooperating institutions from Octo- ber 82 and from August 84 respectively in a randomized chemotherapy trial. As of December 84, 102 pts with histologically proven NOBC, UICC stage III (not susceptible of radiothera- py either because previously irradiated or because of too bulky disease) or IV, PS 50, measurable or evaluable lesions, no pre~ious CT, were ~andomized to CAM~ (C 300 mg/m- i.v., A 20 mg/m ~ i.v 2, M 15 mg/m i.v. day 1 and 8 and P i00 mg/m ~rally day i-i0, every 28 days) or DE (D 20 mg/m ~ i.v. and E 75 mg/m i.v. day 1-5, every 21 days. One pt was not eligible. The characteristics of the 101 pts were (CAMP/ DE): number of pts 46/55, males 41/46, females 5/9, median age 58/58 years, stage III 13/14, stage IV 33/41, PS > 70 32/38, PS < 70 14/17. Histology was (CAMPTDE): squamous 36/36, adeno 9/14, bronchiolo-alveolar 0/3, large cell i/0, unclassified NOBC 0/2. 126 CAMP and 160 DE cycles were administered. Response was (CAMP/ DE): not evaluable 6/8, not yet evaluable 0/3, complete remission 0/2, partial remission I0/15, stabilization 17/19, progression 13/8; respon- se rate 25% (C.L. 12-38%)/39% (C.L. 27-51%). Toxicity was acceptable in both treatment arms. Actuarial median survival (all eligible pts) was (CAMP/DE): 20/34 wks, (p=0.04). At this preliminary analysis, DE seems to be able to induce a longer survival than CAMP.

The study is still ongoing.

5-Fluorouracil (FU), Etoposide (VPI6) and Cis- platin (DDP) Combination (FED) Chemotherapy (CT) in Non-Small Cell LLmg Cancer (NSCLC). Sridhar, K.S., Groh, E., Varki, J., Davila, E., Donnelly, E., Benetto, P., Beattie, E.J. Com- prehensive Cancer Center, University of Miami School of Medicine, and V.A. Hospital, Miami, FI., U.S.A.

FED is based on in vitro synergy of DDP with both VP-16 and FU and on differing dose

limiting toxicities consisting of mucositis